-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, K3NCaoI6HP+XUrzxx8940aCkc6iDtwgcaNKWJ/GNYWdzrBJ3+EEQ1eRFOa2t0MDX MV+qLERjxTkvvlZMGlqFNg== 0000950123-01-502774.txt : 20010522 0000950123-01-502774.hdr.sgml : 20010522 ACCESSION NUMBER: 0000950123-01-502774 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20010518 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 20010521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BARR LABORATORIES INC CENTRAL INDEX KEY: 0000010081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221927534 STATE OF INCORPORATION: NY FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-09860 FILM NUMBER: 1643962 BUSINESS ADDRESS: STREET 1: 2 QUAKER RD BOX 2900 CITY: POMONA STATE: NY ZIP: 10970-0519 BUSINESS PHONE: 9143621100 MAIL ADDRESS: STREET 1: 2 QUAKER RD STREET 2: BOX 2900 CITY: POMONA STATE: NY ZIP: 10970-0519 8-K 1 y49503e8-k.txt BARR LABORATORIES, INC. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report MAY 18, 2001 BARR LABORATORIES, INC. (Exact name of registrant as specified in its charter)
New York 1-9860 22-1927534 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Identification No.)
Two Quaker Road, P.O. Box 2900, Pomona, New York 10970-0519 (Address of principal executive offices) (Zip code) (845) 362-1100 (Registrant's telephone number, including area code) 1 2 BARR LABORATORIES, INC. CURRENT REPORT DATED MAY 18, 2001 Item 5. Other Events See attached Exhibit 99.4, press release announcing that the Company received a subpoena, issued by the Commonwealth of Massachusetts Office of the Attorney General, for the production of documents related to pricing and reimbursement of select products in Massachusetts. Item 7. Financial Statements and Exhibits (c) Exhibit Number Exhibit 99.4 Registrant's May 17, 2001 press release announcing that the Company received a subpoena, issued by the Commonwealth of Massachusetts Office of the Attorney General, for the production of documents related to pricing and reimbursement of select products in Massachusetts. 2 3 BARR LABORATORIES, INC. CURRENT REPORT DATED MAY 18, 2001 SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BARR LABORATORIES, INC. Date: May 18, 2001 /S/ William T. McKee --------------------------- William T. McKee Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 3 EX-99.4 2 y49503ex99-4.txt PRESS RELEASE 1 Exhibit 99.4 [BARR LABORATORIES, INC. LOGO] 2 Quaker Road, P.O. Box 2900 N E W S R E L E A S E Pomona, NY 10970 845-362-1100 CONTACT: Carol A. Cox, 845-348-6808 EMAIL: ccox@barrlabs.com BARR CONFIRMS RECEIPT OF MASSACHUSETTS SUBPOENA POMONA, NEW YORK, MAY 17, 2001... Barr Laboratories, Inc. (NYSE-BRL) today confirmed that it has received a subpoena, issued by the Commonwealth of Massachusetts Office of the Attorney General, for the production of documents related to pricing and reimbursement of select products in Massachusetts. Barr is one of a number of pharmaceutical companies that has received such subpoenas. The Company said it is cooperating with the inquiry and believes that all of its product agreements and pricing decisions have been lawful and proper. Barr Laboratories, Inc. is a specialty pharmaceutical company engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals. Safe Harbor Statement: To the extent that any statements made in this release contain information that is not historical, these statements are essentially forward-looking. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include: the timing and outcome of legal proceedings; the difficulty in predicting the timing of U.S. Food and Drug Administration ("FDA") approvals; the difficulty in predicting the timing and outcome of court decisions on patent challenges; the court and FDA's decisions on exclusivity periods; market and customer acceptance and demand for new pharmaceutical products; the ability to market proprietary products; the impact of competitive products and pricing; timing and success of product development and launch; availability of raw materials; the regulatory environment; fluctuations in operating results; and, other risks detailed from time-to-time in the Company's filings with the Securities and Exchange Commission. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "believes," "may," "could" "estimates," "intends" and other words of similar meaning. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update any forward-looking statements. [EDITOR'S ADVISORY: Barr Laboratories, Inc. news releases are available free of charge through PR Newswire's News On-Call fax service. For a menu of Barr's previous releases, or to receive a specific release via fax call: 800-758-5804 - -- ext. 089750. Barr news releases and corporate information are also available on Barr's home page (www.barrlabs.com). ] 4 -----END PRIVACY-ENHANCED MESSAGE-----